MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia.
Bioactive lipids
Chemokines
Cytokines
ERK1/2
JNK
Lipopolysaccharide
Neuroinflammation
p38
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
23 Apr 2020
23 Apr 2020
Historique:
received:
13
11
2019
accepted:
08
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
19
3
2021
Statut:
epublish
Résumé
In the extracellular environment, lysophosphatidic acid (LPA) species are generated via autotaxin (ATX)-mediated hydrolysis of lysophospholipid precursors. Members of the LPA family are potent lipid mediators transmitting signals via six different G protein-coupled LPA receptors (LPAR1-6). The LPA signaling axis is indispensable for brain development and function of the nervous system; however, during damage of the central nervous system, LPA levels can increase and aberrant signaling events counteract brain function. Here, we investigated regulation of the ATX/LPA/LPAR axis in response to lipopolysaccharide-induced systemic inflammation in mice and potential neurotoxic polarization programs in LPA-activated primary murine microglia. In vivo, LPAR1-6 expression was established by qPCR in whole murine brain homogenates and in FACS-sorted microglia. ELISAs were used to quantitate LPA concentrations in the brain and cyto-/chemokine secretion from primary microglia in vitro. Transcription factor phosphorylation was analyzed by immunoblotting, and plasma membrane markers were analyzed by flow cytometry. We used MAPK inhibitors to study signal integration by the JNK, p38, and ERK1/2 branches in response to LPA-mediated activation of primary microglia. Under acute and chronic inflammatory conditions, we observed a significant increase in LPA concentrations and differential regulation of LPAR, ATX (encoded by ENPP2), and cytosolic phospholipase A2 (encoded by PLA2G4A) gene expression in the brain and FACS-sorted microglia. During pathway analyses in vitro, the use of specific MAPK antagonists (SP600125, SB203580, and PD98059) revealed that JNK and p38 inhibition most efficiently attenuated LPA-induced phosphorylation of proinflammatory transcription factors (STAT1 and -3, p65, and c-Jun) and secretion of IL-6 and TNFα. All three inhibitors decreased LPA-mediated secretion of IL-1β, CXCL10, CXCL2, and CCL5. The plasma membrane marker CD40 was solely inhibited by SP600125 while all three inhibitors affected expression of CD86 and CD206. All MAPK antagonists reduced intracellular COX-2 and Arg1 as well as ROS and NO formation, and neurotoxicity of microglia-conditioned media. In the present study, we show that systemic inflammation induces aberrant ATX/LPA/LPAR homeostasis in the murine brain. LPA-mediated polarization of primary microglia via MAPK-dependent pathways induces features reminiscent of a neurotoxic phenotype.
Sections du résumé
BACKGROUND
BACKGROUND
In the extracellular environment, lysophosphatidic acid (LPA) species are generated via autotaxin (ATX)-mediated hydrolysis of lysophospholipid precursors. Members of the LPA family are potent lipid mediators transmitting signals via six different G protein-coupled LPA receptors (LPAR1-6). The LPA signaling axis is indispensable for brain development and function of the nervous system; however, during damage of the central nervous system, LPA levels can increase and aberrant signaling events counteract brain function. Here, we investigated regulation of the ATX/LPA/LPAR axis in response to lipopolysaccharide-induced systemic inflammation in mice and potential neurotoxic polarization programs in LPA-activated primary murine microglia.
METHODS
METHODS
In vivo, LPAR1-6 expression was established by qPCR in whole murine brain homogenates and in FACS-sorted microglia. ELISAs were used to quantitate LPA concentrations in the brain and cyto-/chemokine secretion from primary microglia in vitro. Transcription factor phosphorylation was analyzed by immunoblotting, and plasma membrane markers were analyzed by flow cytometry. We used MAPK inhibitors to study signal integration by the JNK, p38, and ERK1/2 branches in response to LPA-mediated activation of primary microglia.
RESULTS
RESULTS
Under acute and chronic inflammatory conditions, we observed a significant increase in LPA concentrations and differential regulation of LPAR, ATX (encoded by ENPP2), and cytosolic phospholipase A2 (encoded by PLA2G4A) gene expression in the brain and FACS-sorted microglia. During pathway analyses in vitro, the use of specific MAPK antagonists (SP600125, SB203580, and PD98059) revealed that JNK and p38 inhibition most efficiently attenuated LPA-induced phosphorylation of proinflammatory transcription factors (STAT1 and -3, p65, and c-Jun) and secretion of IL-6 and TNFα. All three inhibitors decreased LPA-mediated secretion of IL-1β, CXCL10, CXCL2, and CCL5. The plasma membrane marker CD40 was solely inhibited by SP600125 while all three inhibitors affected expression of CD86 and CD206. All MAPK antagonists reduced intracellular COX-2 and Arg1 as well as ROS and NO formation, and neurotoxicity of microglia-conditioned media.
CONCLUSION
CONCLUSIONS
In the present study, we show that systemic inflammation induces aberrant ATX/LPA/LPAR homeostasis in the murine brain. LPA-mediated polarization of primary microglia via MAPK-dependent pathways induces features reminiscent of a neurotoxic phenotype.
Identifiants
pubmed: 32326963
doi: 10.1186/s12974-020-01809-1
pii: 10.1186/s12974-020-01809-1
pmc: PMC7178949
doi:
Substances chimiques
Lysophospholipids
0
Receptors, Lysophosphatidic Acid
0
Phosphoric Diester Hydrolases
EC 3.1.4.-
alkylglycerophosphoethanolamine phosphodiesterase
EC 3.1.4.39
lysophosphatidic acid
PG6M3969SG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127Subventions
Organisme : Austrian Science Fund
ID : DK MOLIN-W1241
Organisme : Medical University of Graz
ID : DK MOLIN-W1241
Organisme : Österreichische Nationalbank
ID : 17600
Organisme : BioTechMed Graz
ID : n.a.
Organisme : Franz Lanyar Stiftung
ID : 411
Références
Nat Neurosci. 2019 Jan;22(1):78-90
pubmed: 30559476
J Neurochem. 2008 Oct;107(1):152-60
pubmed: 18680554
Cell Tissue Res. 2010 Jul;341(1):23-32
pubmed: 20495828
J Neuroinflammation. 2014 Feb 27;11:37
pubmed: 24576351
Nat Neurosci. 2016 Jul 26;19(8):987-91
pubmed: 27459405
Biochim Biophys Acta. 2013 Jan;1831(1):61-73
pubmed: 22960381
Nanomedicine (Lond). 2018 Jul;13(13):1607-1621
pubmed: 30028250
Glia. 2018 Dec;66(12):2531-2549
pubmed: 30195261
Free Radic Biol Med. 2012 Jan 15;52(2):516-26
pubmed: 22155714
Neuropharmacology. 2010 Mar;58(3):561-8
pubmed: 19951717
Biochim Biophys Acta. 2008 Sep;1781(9):513-8
pubmed: 18621144
Development. 2015 Apr 15;142(8):1390-5
pubmed: 25852197
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
Curr Med Chem. 2008;15(21):2122-31
pubmed: 18781939
Lancet Respir Med. 2018 Aug;6(8):627-635
pubmed: 29792287
PLoS One. 2015 Jul 21;10(7):e0133619
pubmed: 26196781
Neuropharmacology. 2017 Nov;126:97-107
pubmed: 28859883
J Neuroinflammation. 2019 Apr 11;16(1):83
pubmed: 30975172
Nat Rev Neurosci. 2018 Mar;19(3):138-152
pubmed: 29416128
Neuron. 2015 Feb 18;85(4):669-82
pubmed: 25695267
Dev Dyn. 2019 May;248(5):375-395
pubmed: 30847983
Acta Neuropathol Commun. 2017 Jun 2;5(1):42
pubmed: 28578681
Neuropeptides. 2019 Aug;76:101938
pubmed: 31255353
Mol Pain. 2009 Nov 13;5:64
pubmed: 19912636
J Neuroinflammation. 2017 Dec 19;14(1):253
pubmed: 29258556
J Neurosci. 2012 Aug 15;32(33):11330-42
pubmed: 22895716
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
J Cell Biochem. 2014 Dec;115(12):2123-32
pubmed: 25053164
Annu Rev Physiol. 2017 Feb 10;79:619-643
pubmed: 27959620
J Cell Biol. 2018 Jan 2;217(1):315-328
pubmed: 29196462
Eur J Neurosci. 2004 Mar;19(6):1469-74
pubmed: 15066143
Annu Rev Immunol. 2009;27:119-45
pubmed: 19302036
J Neuroinflammation. 2011 Jul 06;8:79
pubmed: 21733175
J Lipid Res. 2014 Jul;55(7):1192-214
pubmed: 24643338
Prog Lipid Res. 2015 Apr;58:76-96
pubmed: 25704398
Cell Mol Life Sci. 2007 Jan;64(2):230-43
pubmed: 17192809
Front Pharmacol. 2017 Feb 16;8:48
pubmed: 28275350
J Neurochem. 2012 Oct;123(1):113-23
pubmed: 22823229
Stroke. 2017 Dec;48(12):3336-3346
pubmed: 29114096
Mol Cancer. 2010 Mar 31;9:71
pubmed: 20356387
Semin Cell Dev Biol. 2004 Oct;15(5):477-89
pubmed: 15271293
Brain Behav Immun. 2018 Aug;72:34-44
pubmed: 29128611
Science. 2010 Nov 5;330(6005):841-5
pubmed: 20966214
Cell Death Dis. 2015 Mar 26;6:e1702
pubmed: 25811799
Brain Res. 2015 Dec 2;1628(Pt B):288-297
pubmed: 26341532
Eur J Med Chem. 2018 Jun 10;153:105-115
pubmed: 28923363
Pain. 2017 Apr;158 Suppl 1:S55-S65
pubmed: 28151833
J Exp Med. 2019 Jan 7;216(1):60-70
pubmed: 30504438
Nat Rev Immunol. 2014 Jul;14(7):463-77
pubmed: 24962261
J Neuroinflammation. 2016 Aug 26;13(1):205
pubmed: 27565558
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Trends Pharmacol Sci. 2006 Jun;27(6):317-23
pubmed: 16678913
Prog Neurobiol. 2019 Jul;178:101612
pubmed: 30954517
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1237-1245
pubmed: 30071304
Science. 2016 Aug 19;353(6301):aad8670
pubmed: 27338705
Front Cell Neurosci. 2019 Nov 29;13:531
pubmed: 31849616
Proteomics. 2010 Jan;10(1):141-58
pubmed: 19899077
J Biol Chem. 2001 Jul 13;276(28):25946-52
pubmed: 11340076
J Neurosci. 2015 Jul 15;35(28):10224-35
pubmed: 26180199
Nature. 2019 Feb;566(7744):388-392
pubmed: 30760929
Trends Neurosci. 2000 Jun;23(6):259-64
pubmed: 10838595
J Pharmacol Exp Ther. 2016 Oct;359(1):207-14
pubmed: 27516465